Delivery Order SPE2DB24D2013-SPE2DB25FCJWU
- Not listed
- The Defense Logistics Agency awarded a $3,537.17 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL unit doses. The contract, which is a non-set-aside competitive award with an ultimate completion date of July 25, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 15, 2025. This firm fixed-price, non-set-aside delivery order, which is due for completion by September 16, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $6,530.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a single pharmaceutical product delivery executed under the company's existing contract vehicle with DLA. Mounjaro is a tirzepatide-based diabetes medication, consistent with AmerisourceBergen's extensive portfolio of...
- The Defense Logistics Agency awarded a $11,495.12 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 mL pens on May 27, 2025, with completion scheduled for May 28, 2025. This competitively awarded, firm fixed-price contract requires delivery to the company's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a delivery order valued at $6,724.34 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on July 2, 2025, with an ultimate completion date of July 3, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 22, 2025, with a ceiling value of $2,176.72 and an ultimate completion date of September 23, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive procurement process. The point of performance is located at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $1,904.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 10 mg/0.5 mL pens on June 27, 2025, with a completion date of June 30, 2025. Mounjaro is a tirzepatide-based diabetes medication used for glycemic control and weight management. This non-competitive delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen injections with a ceiling value of $1,088.36. This contract, issued on May 23, 2025, represents a firm fixed price delivery order with an ultimate completion date of May 27, 2025 and carries no set-aside designation. The award was made through competitive procurement processes and serves as a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens valued at $13,934.62 on May 6, 2025, with completion scheduled for May 7, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $6,235.50. This competitively awarded, firm fixed-price delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation,...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCJWUDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $33,315.11 to AmerisourceBergen Drug Corp for the supply of Mounjaro 5 mg/0.5 mL pens (0.5 mL units). The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 13, 2025, and was competitively awarded without set-aside designations. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value and runs through December 2026. The delivery order represents pharmaceutical procurement for federal military and veteran healthcare systems through DLA's medical supply chain. Mounjaro (tirzepatide) is a GLP-1 receptor agonist used in diabetes treatment, consistent with AmerisourceBergen's extensive portfolio of specialty pharmaceutical products supplied to the Defense Health Agency and other federal healthcare organizations. The SPE2DX contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.3k | 8/12/25 |